The Medical Letter on Drugs and Therapeutics
Beta-Adrenergic Blockers and Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Three retrospective studies have recently reported an association between beta-blocker use and a reduction in breast cancer metastasis and recurrence. No prospective, randomized trials have been published.1

MECHANISM OF ACTION — Activation of the beta-adrenergic receptor has been implicated in multiple steps of metastasis formation, including tumor cell proliferation, angiogenesis, and migration of tumor cells through the extracellular matrix. In a mouse model, beta-adrenergic activation had a negligible effect on primary breast tumor growth, but increased metastasis 30-fold.2

THE STUDIES — One retrospective study evaluated beta-blocker use in 466 women with early-stage breast cancer. Among these women, 43 had been treated with a beta blocker (propranolol, atenolol, bisoprolol or timolol) for hypertension, and 49 had ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Beta-Adrenergic Blockers and Breast Cancer
Article code: 1382c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian